Mr. Speaker, the facts were clear at the time the drug was administered and it was clear there was a problem.
DND participation in the safety monitoring study would have alerted Health Canada of the sometimes intolerable side effects of the drug mefloquine which were well documented at the time by Canadian military doctors.
Can the minister tell the House why his department did not insist that DND participate fully in the safety monitoring study before licensing mefloquine for general use by Canadians?